\r\n![\"Bio-Rad](\"https:\/\/clixtrac.com\/banner\/311442.jpg\" "\\"Bio-Rad")
<\/a>\r\n<\/p>\n<\/div><\/section><\/div>
![\"\"](\"https:\/\/clixtrac.com\/banner\/283809.png\" "\\"\\"")
<\/a>\r\n<\/div><\/p>\n<\/div><\/section>\n
Heiner Dreismann joins Noscendo\u2019s Board of Directors<\/h1>E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nNoscendo, a leading diagnostic company for identification and assessment of bloodstream associated pathogens and other infections has appointed Heiner Dreismann, former President and CEO of Roche Molecular Systems, to its Board of Directors.<\/h3>\n<\/p>\n
Dr. Dreismann, a microbiologist by training, contributed significantly to the development and commercialization of an extensive portfolio of products within the microbiology space, among others, enforcing Roche\u2019s industry leadership in Molecular Diagnostics. Other senior positions he held in Roche included Head of Global Business Development, Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee adding tremendous market understanding to Noscendo\u2019s Board of Directors.<\/p>\n
Dr. Philip Stevens, Managing Director of Noscendo, said: \u201cWe are pleased to be able to draw on Dr. Dreismann’s invaluable experience to strengthen our leading position in nextgeneration medical microbiology and create the long-awaited change in medical microbiology.\u201d<\/p>\n
Dr. Dreismann commented: \u201cThe clinical microbiology space will benefit significantly from the disruptive technology and business model innovation Noscendo is providing by applying its proprietary Artificial Intelligence derived algorithms for a deep analysis of sequence based information. In particular, the breadth and versatility of its current and future product pipeline is unparalleled.\u201d<\/p>\n
Heiner Dreismann<\/em><\/p>\n<\/div><\/section>
\n
Noscendo, a leading diagnostic company for identification and assessment of bloodstream associated pathogens and other infections has appointed Heiner Dreismann, former President and CEO of Roche Molecular Systems, to its Board of Directors.<\/h3>\n<\/p>\n
Dr. Dreismann, a microbiologist by training, contributed significantly to the development and commercialization of an extensive portfolio of products within the microbiology space, among others, enforcing Roche\u2019s industry leadership in Molecular Diagnostics. Other senior positions he held in Roche included Head of Global Business Development, Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee adding tremendous market understanding to Noscendo\u2019s Board of Directors.<\/p>\n
Dr. Philip Stevens, Managing Director of Noscendo, said: \u201cWe are pleased to be able to draw on Dr. Dreismann’s invaluable experience to strengthen our leading position in nextgeneration medical microbiology and create the long-awaited change in medical microbiology.\u201d<\/p>\n
Dr. Dreismann commented: \u201cThe clinical microbiology space will benefit significantly from the disruptive technology and business model innovation Noscendo is providing by applying its proprietary Artificial Intelligence derived algorithms for a deep analysis of sequence based information. In particular, the breadth and versatility of its current and future product pipeline is unparalleled.\u201d<\/p>\n
Heiner Dreismann<\/em><\/p>\n<\/div><\/section>
\n
\n